Want to join the conversation?
$MRK's data on KEYTRUDA (pembrolizumab), the company’s cancer therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 – 11. KEYTRUDA is a prescription medicine to treat a kind of skin cancer called melanoma.
Looking forward for $STT’s 2017 first quarter earnings results. Is it possible for them to outperform their estimates?
$HAL has cautioned that its 1Q profit is likely to miss projections. I’m expecting EPS to be in low single digits.!
$GOOG is losing more advertisers after the boycotts over extremist ads. Future is not so bright for Google in the advertising sector..!